Key facts
- This page summarizes Anthony Welters's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 27 Aug 2026, 18:44.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Sale
Options Exercise
Sale
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.
Footnote F2
Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Footnote F3
Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Footnote F4
Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Footnote F5
Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
Footnote F6
100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020.
Footnote F7
25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021.